A Modular Platform for Effector Discovery in Induced-Proximity Lysine Acetylation

This paper presents a modular platform that utilizes compound-dependent or nanobody-mediated induced proximity to rapidly screen and identify effective acetyltransferase effectors for site-specific lysine acetylation of diverse protein substrates in living cells, thereby accelerating the development of targeted chemical probes for post-translational modification editing.

The Gist

Imagine your body is a bustling city made of trillions of tiny workers (proteins). These workers don't just sit still; they have "badges" or "stickers" (called Post-Translational Modifications) that tell them what to do, where to go, and when to stop. One of the most important stickers is acetylation, which acts like a "turn on" switch for many proteins.

For a long time, scientists have wanted to be able to stick these "turn on" badges onto specific workers at will, to see what happens or to fix broken systems. But doing this has been like trying to hire a specific painter to paint a specific wall in a massive, chaotic construction site. You have to build a custom ladder, a custom scaffold, and a custom paintbrush for every single wall, and it takes months of trial and error to figure out if the painter even knows how to paint that specific wall.

This paper introduces a "Modular Lego Platform" that solves this problem.

Here is how it works, broken down into simple concepts:

1. The Problem: The "Trial-and-Error" Trap

Previously, if a scientist wanted to put an acetylation sticker on a specific protein (like p53, a famous tumor suppressor), they had to design a complex chemical molecule (a "heterobifunctional molecule") to grab the protein and drag a "painter" (an enzyme called an acetyltransferase) right next to it.

• The Catch: They would spend months building this chemical molecule, only to find out afterward that the painter they chose didn't actually know how to paint that specific wall. It was a huge waste of time and resources.

2. The Solution: A "Plug-and-Play" System

The researchers built a modular platform. Think of it like a universal power strip with different outlets.

• The Base: They created a system where they can easily swap out the "painter" (the enzyme) and the "target" (the protein) without rebuilding the whole machine.
• The Glue: They use two different ways to stick the painter to the target:
  1. The Chemical Glue: A small molecule (like a magnet) that snaps two pieces together only when you add it.
  2. The Nanobody Glue: A tiny, super-strong protein hook that grabs the target directly, no chemical needed.

3. The Experiment: Testing the Painters

To prove their system worked, they tried to "paint" (acetylate) three different targets:

• GFP: A glowing protein (like a test dummy).
• Histone H3: A protein that helps package DNA (like a spool of thread).
• p53: A critical protein that stops cancer.

They tested different "painters" (enzymes like p300, GCN5, Tip60, and even a tiny ancient enzyme from archaea called PAT).

4. The Big Discovery: The Painter Matters More Than the Glue

Here is the most important finding, explained with an analogy:
Imagine you have a wall (the protein) and you bring a painter to it.

• If you bring Painter A (p300), they might paint the whole wall, the ceiling, and the floor because they are a bit messy and love to paint everywhere.
• If you bring Painter B (GCN5), they are very precise and only paint one specific corner.
• If you bring Painter C (PAT), they are tiny and only paint a tiny dot, leaving the rest of the room untouched.

The paper shows that the "glue" (the proximity system) doesn't decide where the paint goes; the "painter" (the enzyme) does.

This is huge because it means scientists can now use this Lego platform to quickly test: "If I want to fix this specific protein, which painter should I hire?" They can try ten different painters in a few days using their modular system, find the one that paints exactly the right spot, and then build the final chemical tool.

5. Why This Matters

• Speed: It turns a process that used to take years of guessing into a process that takes days of testing.
• Precision: It allows scientists to find the "perfect fit" enzyme for a specific job, avoiding the "messy painter" (p300) that paints too much of the cell.
• New Tools: They even brought in a "foreign" painter (PAT from ancient bacteria) that works well on human proteins but doesn't mess up the rest of the cell. This is like hiring a specialist from another country who knows exactly how to fix your specific engine without touching the rest of the car.

In Summary:
This paper gives scientists a universal testing kit. Instead of building a custom car for every road trip, they now have a chassis where they can easily swap out the engine (the enzyme) and the driver (the target) to see which combination drives the best. Once they find the winning combination, they can build the final, permanent vehicle (the drug or chemical probe) with confidence.

Technical Summary

1. Problem Statement

Post-translational modifications (PTMs), such as lysine acetylation, are critical regulators of cellular function and disease. While "induced-proximity" strategies (e.g., PROTACs, AceTAGs) allow researchers to recruit enzymes to specific proteins to manipulate PTMs, a significant bottleneck exists in their development:

• Empirical Trial-and-Error: Identifying which effector enzyme (e.g., a specific acetyltransferase) effectively modifies a specific target protein is currently empirical.
• Inefficient Workflow: Researchers often synthesize complex heterobifunctional molecules (chemical probes) before validating whether the recruited enzyme can actually modify the intended substrate.
• The Gap: There is a lack of a rapid, modular system to test effector–substrate compatibility in living cells prior to the expensive and time-consuming design of chemical probes.

2. Methodology

The authors developed a modular cloning platform to rapidly assemble and test fusion proteins that induce proximity between a Protein of Interest (POI) and a PTM editing enzyme (effector).

• Modular Design: The system utilizes Gibson assembly to create three-component vectors:
  1. Targeting Domain: Fused to the POI.
  2. Effector Domain: Fused to the PTM editor (acetyltransferase).
  3. Backbone: Standard mammalian expression vectors.
• Induced Proximity Mechanisms: The platform supports two modes of recruitment:
  1. Compound-Dependent: Uses a heterobifunctional molecule (HaloFK7) to dimerize HaloTag7 (fused to the effector) and FKBP12F36V (fused to the POI).
  2. Compound-Independent: Uses a nanobody (e.g., GFP Nanobody, GNb) fused directly to the effector to bind the POI without small molecules.
• Model System: The authors focused on lysine acetylation as a proof-of-concept, recruiting various Lysine Acetyltransferases (KATs) to different substrates.
• Validation Tools: They utilized immunoblotting with site-specific acetylation antibodies, mass spectrometry (MS) for residue-level mapping, and ternary complex pull-down assays.

3. Key Contributions

• Rapid Effector Screening: A unified framework to test multiple acetyltransferases against a single substrate (or vice versa) in living cells without synthesizing new chemical probes for each test.
• Decoupling Discovery from Synthesis: The platform allows researchers to identify "productive" effector–substrate pairs before committing to the synthesis of heterobifunctional molecules.
• Xeno-PTM Editors: Introduction of non-mammalian enzymes (specifically the archaeal acetyltransferase PAT) as tools to reduce off-target effects in mammalian cells.
• Nanobody Integration: Demonstration that nanobody-mediated recruitment is a viable, stable, and tag-free alternative to small-molecule induced proximity.

4. Key Results

A. Proof of Concept: eGFP Acetylation

• Compound-Dependent: Recruiting the promiscuous acetyltransferase p300 (via HaloTag7-p300) to FKBP12F36V-eGFP using HaloFK7 resulted in significant, dose-dependent acetylation of eGFP.
  • Specificity: Mass spectrometry identified specific acetylation sites (K156, K158).
  • Catalytic Requirement: A catalytically dead p300 mutant (I1395R) formed the ternary complex but failed to acetylate eGFP, confirming the effect is enzymatic.
• Compound-Independent: Replacing HaloTag7 with a GFP Nanobody (GNb) fused to p300 successfully induced binary complex formation and eGFP acetylation without small molecules.

B. Substrate Specificity and Histone Acetylation (H3)

• The platform was tested on Histone H3 (a nuclear substrate).
• Effector Dictates Pattern: The site-specific acetylation pattern was determined by the recruited enzyme, not just the proximity:
  • p300: Induced H3K9Ac and H3K27Ac.
  • GCN5 (GNAT family): Induced H3K9Ac and H3K27Ac but with less proteome-wide promiscuity than p300.
  • Tip60 (MYST family): Induced H3K9Ac and H3K14Ac, but not H3K27Ac (consistent with Tip60's known substrate preference).
• Conclusion: The platform successfully recapitulates native enzyme specificity, allowing researchers to "program" specific histone marks.

C. Targeted p53 Acetylation and Xeno-Editors

• p53 Targeting: Recruitment of p300 to FKBP12F36V-p53 successfully increased acetylation at K382 (a key activation site) and stabilized p53 levels (likely by inhibiting MDM2 binding).
• Xeno-PTM Editor (PAT): To address the off-target promiscuity of p300, the authors recruited PAT (an archaeal acetyltransferase).
  • PAT successfully acetylated p53 K382 and stabilized the protein.
  • Crucially, PAT caused significantly less global proteome-wide acetylation compared to p300, demonstrating its utility as a precise, low-background tool.

5. Significance and Impact

• Accelerated Probe Development: This platform bridges the gap between high-throughput effector discovery and chemical probe development. Researchers can now validate biological hypotheses and identify optimal effectors rapidly before investing in molecule synthesis.
• Precision PTM Editing: By demonstrating that different acetyltransferases yield distinct acetylation patterns on the same substrate, the work enables the precise engineering of PTM landscapes for therapeutic or mechanistic studies.
• Reduced Off-Target Effects: The successful use of the archaeal enzyme PAT introduces a new class of "xeno-PTM editors" that can modify mammalian proteins with high specificity and minimal background noise.
• Generalizability: While demonstrated with acetylation, the modular Gibson assembly strategy is applicable to other PTMs (ubiquitination, phosphorylation, etc.) and various recruitment modalities (nanobodies, small molecules), making it a versatile toolbox for cell biology and drug discovery.